홈 > 시장보고서 > 의약품 > 처방약

시장보고서

상품코드

2128958

질환 조절약 시장 : 약제 클래스별, 적응증별, 치료법별, 투여 경로별, 유통 채널별, 국가별, 지역별 - 업계 분석, 시장 규모, 시장 점유율 및 예측(2026-2033년)

Disease-Modifying Agents Market, By Drug Class, By Indication, By Therapy Type, By Route of Administration, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033

발행일: 2026년 08월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 254 Pages | 배송안내 : 2-3일 (영업일 기준)

가격

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 3,250

￦ 4,433,000

PDF (5 User License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,560

￦ 6,220,000

PDF & Excel (Enterprise User License)

PDF & Excel 보고서를 동일 기업 내 모든 사용자가 사용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,650

￦ 7,707,000

※ 부가세 별도

한글목차

영문목차

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

질환 조절약 시장 규모는 2025년에 61억 510만 달러로 평가되었고, 2026-2033년 CAGR 6.6%로 성장할 전망입니다.

질환 조절약이란 단순히 증상을 치료하는 데 그치지 않고, 자가면역 반응이나 염증 과정과 같은 질환의 근본적인 기전을 수정하여 그 진행을 억제하는 처방약의 일종입니다. 이 시장에는 메토트렉세이트, 설파살라진, 레플루노미드, 하이드록시클로로퀸, 미코페놀산, 인터페론 β, 글라티라머 아세테이트 등 다양한 기존 질환 조절약(TDMAs)가 포함됩니다.

대상 질환으로는 류마티스 관절염, 다발성 경화증(MS), 루푸스 및 기타 자가면역 질환이 포함됩니다. 다발성 경화증 국제 연맹(MS International Federation)에 따르면, 2025년 기준으로 전 세계적으로 약 290만 명이 다발성 경화증(MS)을 앓고 있습니다. 시장 전체는 이미 자리 잡은 제네릭 의약품이 주류를 이루고 있지만, 차별화된 주사제를 통한 치료법에 대한 수요도 존재합니다. 또한, 치료 선택은 질환의 중증도, 안전성, 모니터링 필요성 및 치료 옵션의 우선순위에 따라 달라집니다. 따라서 각 의약품의 유용성은 그 적응증과 작용기전에 따라 결정됩니다.

질환 조절약 시장 : 시장 역학

만성 자가면역 질환 치료 대상 환자 수 증가

자가면역 질환 및 염증성 질환의 치료 대상 인구가 전반적으로 확대되고 있는 것은 기존 질병 수습 요법의 대상 환자층 확대에 기여하고 있습니다. 특히, 2025년 CDC의 분석에 따르면, 미국에서는 관절염으로 진단받은 성인이 6,710만 명이었으며, 그중 1,060만 명이 류마티스 관절염 환자입니다. 또한, 국제 다발성 경화증 연맹(MSIF)의 보고에 따르면, 전 세계적으로 290만 명이 다발성 경화증을 앓고 있습니다. 그 결과, 질환 유병률의 상승에 따라 일반적으로 장기간 치료가 필요한 만성 질환을 대상으로 하는 이러한 치료제의 사용이 촉진되고 있습니다. 따라서 치료에 대한 지속적인 수요가 치료 시작률, 경과 관찰, 치료법 변경 및 복약 순응도에 영향을 미치고 있습니다. 이처럼 질환의 존재 자체가 의약품의 지속적인 사용에 기여하고 있습니다. 또한, 약물 군의 선정은 확립된 치료 요법, 안전성, 투여 편의성 및 질환 조절 상태에 따라 달라집니다.

질환 조절약 시장 : 시장 세분화 분석 :

세계 질환 조절약 시장은 약물 분류, 적응증, 치료법 유형, 투여 경로, 유통 채널 및 지역을 기준으로 세분화되어 있습니다.

약제 분류별로는 메토트렉세이트, 레플루노미드, 하이드록시클로로퀸, 설파살라진이 특히 류마티스 관절염 및 기타 염증성 질환에서 확립된 장기 사용 실적을 보유하고 있기 때문에 기존의 합성 질환 수정 항류마티스제(DMARD)가 총 매출의 큰 비중을 차지하고 있습니다. 메토트렉세이트는 중등도에서 중증의 류마티스 관절염을 앓고 있는 많은 환자에게 여전히 1순위로 선택되는 DMARD입니다. 생물학적 제제 및 표적 합성 약제는 DMARD 중에서도 빠르게 발전하고 있는 분야입니다. 이는 주로 TNF/JAK 경로를 표적으로 하는 능력에 기인하며, 그 결과 질환 관리가 개선되어 기존 치료법으로 충분한 효과를 얻지 못하는 경우, 이러한 약제가 2차 치료제로 널리 받아들여지고 있습니다. 세계보건기구(WHO)의 추정에 따르면, 전 세계적으로 약 1,800만 명이 류마티스 관절염을 앓고 있는 것으로 알려져 있습니다.

질환 조절약 시장 : 지역별 분석

북미는 전문 의료 인프라의 구축, 확립된 보험 환급 제도, 그리고 질환 수정 약물의 지속적인 사용을 가능하게 하는 자가면역 질환의 높은 유병률로 인해 여전히 중요한 전략적 거점으로 남아 있습니다. 미국 질병통제예방센터(CDC)의 2025년 추정에 따르면, 미국에는 관절염으로 진단받은 성인 환자가 6,710만 명이며, 그중 1,060만 명이 류마티스 관절염을 앓고 있습니다. 따라서 기존 DMARDs에게는 충분히 큰 목표 환자층이 존재합니다. 다발성 경화증의 추가는 장기적인 치료와 모니터링이 필요한 또 다른 전문적인 적응증이 됩니다. 또한, 규제 당국의 동향은 제품 접근성 및 대체 의약품 사용에 영향을 미칩니다. FDA는 2025년, 다발성 경화증 치료제로 시포니모드 및 클라드리빈의 제네릭 의약품을 승인했습니다. 따라서 북미에는 충분한 임상적 수요가 존재할 뿐만 아니라, 근거 기반의 편의성이 높은 치료 옵션을 촉진하는 확립된 규제 환경이 갖춰져 있습니다.

유럽은 확립된 류마티스학 및 신경학 의료 체계, 체계적인 의약품 평가, 그리고 만성 면역 매개 질환의 지속적인 관리를 통해 중요한 시장으로 자리 잡고 있습니다. 영국 다발성 경화증 협회(UK MS Society)에 따르면, 영국에는 15만 명 이상의 다발성 경화증 환자가 있으며, 매년 7,100건 이상의 신규 사례가 진단되고 있어 신경 질환 치료에 대한 지속적인 수요가 나타나고 있습니다. 규제 동향에서도 제품 교체가 지속적으로 이루어지고 있음이 드러나고 있습니다. 2025년, 유럽의약품청(EMA)은 재발-완화형 다발성 경화증 치료를 목적으로 하는 테고밀푸마르산염의 제네릭 의약품 ‘Riulvy’에 대한 판매 승인을 부여했습니다. 이러한 승인은 제품 선택의 폭을 넓히는 한편, 기존 제품에 대한 대체 압력을 높일 가능성이 있습니다. 기존의 DMARD(질병 수정 항류마티스제)인 메토트렉세이트, 하이드록시클로로퀸, 설파살라진, 레플루노미드는 여전히 지침에 기반한 류마티스학 진료에 포함되어 있습니다.

Disease-modifying agents are a class of prescription drugs that modify the underlying disease mechanisms, such as the autoimmune response or inflammatory process, and reduce their progression, as opposed to only treating the symptoms. The market offers a range of traditional disease-modifying agents (TDMAs), including methotrexate, sulfasalazine, leflunomide, hydroxychloroquine, mycophenolate, interferon beta, and glatiramer acetate.

Disease areas comprise rheumatoid arthritis, multiple sclerosis, lupus, and other autoimmune diseases. According to the MS International Federation, as of 2025, there are approximately 2.9 million people worldwide living with multiple sclerosis (MS). The overall market is dominated by established generic drugs, but there is also a need for differentiated injectable therapies. Additionally, the choice of therapy depends on the severity of the condition, safety, the need for monitoring, and the sequence of treatment options; therefore, the relevance of each drug depends on its indication and mechanism of action.

Disease-Modifying Agents Market- Market Dynamics

Expanding Chronic Autoimmune Disease Treatment Pool

The overall expanding treated population within autoimmune/inflammatory diseases contributes to the addressable base for existing disease-modifying therapies. In particular, according to the 2025 CDC analysis, there are 67.1 million U.S. adults with diagnosed arthritis, including 10.6 million individuals with rheumatoid arthritis. The Multiple Sclerosis International Federation reported that 2.9 million people worldwide are living with multiple sclerosis. As a result, disease prevalence boosts the therapies' utilization as they usually address a chronic condition, which involves long-term treatment courses. Consequently, the continuous need for treatment affects the rate of initiation, monitoring, switches, and adherence. Thus, the presence of diseases contributes to the continuous utilization of drugs. Additionally, the class preference is dependent on the established treatment regimen, safety, convenience of administration, and disease control.

Disease-Modifying Agents Market- Segmentation Analysis:

The Global Disease-Modifying Agents Market is segmented on the basis of Drug Class, Indication, Therapy Type, Route of Administration, Distribution Channel, and Region.

By drug class, Conventional synthetic disease modifying agents (DMARDs) have a large proportion of total revenues due to the well-established and long term usage of methotrexate, leflunomide, hydroxychloroquine and sulfasalazine; especially in rheumatoid and other inflammatory diseases. Methotrexate remains the first line of choice DMARD for many patients who have moderate to severe levels of rheumatoid arthritis. Biologic and targeted synthetic agents are rapidly developing categories of DMARDs. This is primarily being driven by the ability to target TNF/JAK pathways which results in better control of disease and increased acceptance of these agents as second-line treatments when conventional therapies fail to provide an adequate response. It has been estimated by the World Health Organization (WHO) that there are approximately 18 million individuals living with rheumatoid arthritis across the globe.

Disease-Modifying Agents Market- Geographical Insights

North America remains an important strategic location due to specialist infrastructure development, established mechanisms for reimbursements, and the prevalence of autoimmune diseases enabling sustained use of disease-modifying products. According to CDC estimates for 2025, there are 67.1 million adult patients in the United States with diagnosed arthritis, 10.6 million of whom suffer from rheumatoid arthritis. Thus, there is a sufficiently large target patient population for conventional DMARDs. The addition of multiple sclerosis provides another specialized indication requiring prolonged treatment and monitoring. Moreover, regulatory activity impacts product access and substitution: the FDA has approved generic versions of siponimod and cladribine in 2025 for the treatment of multiple sclerosis. Thus, North America has sufficient clinical need combined with a well-established regulatory environment that incentivizes evidence-based, convenient treatment options.

Europe presents a significant market due to the established systems of rheumatology and neurology care, structured medical product assessments, and sustained management of chronic immune-mediated diseases. According to the UK MS Society, there are more than 150,000 people living with multiple sclerosis in the country and more than 7,100 new cases diagnosed each year demonstrating the consistent need for neurological treatments. The regulatory activity also shows continuous product turnover, in 2025, the EMA approved marketing authorization for Riulvy a generic tegomil fumarate intended for treating relapsing remitting multiple sclerosis. Approvals like these may expand product choice while increasing the pressure on the substitution of existing products. Conventional DMARDs remain integrated into guideline-based rheumatology practice-methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide.

Disease-Modifying Agents Market- Competitive Landscape:

Competition is distributed among diversified pharmaceutical companies, specialty immunology developers, and manufacturers supplying established or generic disease-modifying therapies. Differentiation increasingly depends on mechanism, administration frequency, safety profile, clinical evidence, and lifecycle expansion rather than product novelty alone. Novartis illustrates this transition through Kesimpta, its B-cell-directed therapy for relapsing multiple sclerosis. In September 2025, company reported ARTIOS and ALITHIOS findings indicated that more than 90% of relevant participants achieved no evidence of disease activity or remained progression-free under specified treatment settings. Biogen simultaneously maintained an established MS portfolio including Avonex and Plegridy, preserving the relevance of interferon-based therapies. Overall, competitive strength increasingly rests on evidence depth, convenience, and differentiated clinical positioning.

Recent Developments:

In September 2025, Novartis announced new data regarding ARTIOS and ALITHIOS studies on Kesimpta in relapsing multiple sclerosis. Over 90% of patients reached particular disease control objectives, reinforcing the rationale for the use of the drug both initially and after switching.

In July 2025, the European Medicines Agency (EMA)/Neuraxpharm granted marketing authorization to Riulvy, a generic tegomil fumarate, for relapsing-remitting multiple sclerosis. This approval increases the list of European products available for MS treatments.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DISEASE-MODIFYING AGENTS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Biogen Inc.
Merck KGaA
Sanofi
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Novartis AG
F. Hoffmann-La Roche Ltd.
AbbVie Inc.
Johnson & Johnson
Amgen Inc.
Eli Lilly and Company
Bristol Myers Squibb
UCB S.A.
Bayer AG
Viatris Inc.
Fresenius Kabi
Accord Healthcare
Others

GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2020 - 2033

Conventional Synthetic Disease-Modifying Agents
Biologic Disease-Modifying Agents
Targeted Synthetic Agents
Interferons
Monoclonal Antibodies
Immunomodulators
Others

GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY INDICATION- MARKET ANALYSIS, 2020 - 2033

Multiple Sclerosis
Rheumatoid Arthritis
Psoriatic Arthritis
Ankylosing Spondylitis / Axial Spondyloarthritis
Systemic Lupus Erythematosus
Systemic Sclerosis
Others

GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2020 - 2033

Combination therapy
Monotherapy
Others

GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033

Oral
Subcutaneous
Intramuscular
Intravenous / Infusion
Others

GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2020 - 2033

Online Pharmacies
Hospital Pharmacies
Retail Pharmacies
Others

GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Denmark
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Taiwan
Vietnam
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Iran
Qatar
Rest of MEA

1. Disease-Modifying Agents Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Disease-Modifying Agents Market Snippet by Drug Class
- 2.1.2. Disease-Modifying Agents Market Snippet by Indication
- 2.1.3. Disease-Modifying Agents Market Snippet by Therapy Type
- 2.1.4. Disease-Modifying Agents Market Snippet by Route of Administration
- 2.1.5. Disease-Modifying Agents Market Snippet by Distribution Channel
- 2.1.6. Disease-Modifying Agents Market Snippet by Country
- 2.1.7. Disease-Modifying Agents Market Snippet by Region
2.2. Competitive Insights

3. Disease-Modifying Agents Key Market Trends

3.1. Disease-Modifying Agents Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Disease-Modifying Agents Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Disease-Modifying Agents Market Opportunities
3.4. Disease-Modifying Agents Market Future Trends

4. Disease-Modifying Agents Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Disease-Modifying Agents Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Disease-Modifying Agents Market Landscape

6.1. Disease-Modifying Agents Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Disease-Modifying Agents Market - By Drug Class

7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Class, 2025 & 2033 (%)
- 7.1.2. Conventional Synthetic Disease-Modifying Agents
- 7.1.3. Biologic Disease-Modifying Agents
- 7.1.4. Targeted Synthetic Agents
- 7.1.5. Interferons
- 7.1.6. Monoclonal Antibodies
- 7.1.7. Immunomodulators
- 7.1.8. Others

8. Disease-Modifying Agents Market - By Indication

8.1. Overview
- 8.1.1. Segment Share Analysis, By Indication, 2025 & 2033 (%)
- 8.1.2. Multiple Sclerosis
- 8.1.3. Rheumatoid Arthritis
- 8.1.4. Psoriatic Arthritis
- 8.1.5. Ankylosing Spondylitis / Axial Spondyloarthritis
- 8.1.6. Systemic Lupus Erythematosus
- 8.1.7. Systemic Sclerosis
- 8.1.8. Others

9. Disease-Modifying Agents Market - By Therapy Type

9.1. Overview
- 9.1.1. Segment Share Analysis, By Therapy Type, 2025 & 2033 (%)
- 9.1.2. Combination therapy
- 9.1.3. Monotherapy
- 9.1.4. Others

10. Disease-Modifying Agents Market - By Route of Administration

10.1. Overview
- 10.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
- 10.1.2. Oral
- 10.1.3. Subcutaneous
- 10.1.4. Intramuscular
- 10.1.5. Intravenous / Infusion
- 10.1.6. Others

11. Disease-Modifying Agents Market - By Distribution Channel

11.1. Overview
- 11.1.1. Segment Share Analysis, By Distribution Channel, 2025 & 2033 (%)
- 11.1.2. Online Pharmacies
- 11.1.3. Hospital Pharmacies
- 11.1.4. Retail Pharmacies
- 11.1.5. Others

12. Disease-Modifying Agents Market- By Geography

12.1. Introduction
- 12.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
12.2. North America
- 12.2.1. Overview
- 12.2.2. Disease-Modifying Agents Key Manufacturers in North America
- 12.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.2.4. North America Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 12.2.5. North America Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
- 12.2.6. North America Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 12.2.7. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.2.8. North America Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.2.9. U.S.
  - 12.2.9.1. Overview
  - 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.2.9.3. U.S. Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.2.9.4. U.S. Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.2.9.5. U.S. Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.2.9.6. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.2.10. Canada
  - 12.2.10.1. Overview
  - 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.2.10.3. Canada Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.2.10.4. Canada Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.2.10.5. Canada Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.2.10.6. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.3. Europe
- 12.3.1. Overview
- 12.3.2. Disease-Modifying Agents Key Manufacturers in Europe
- 12.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.3.4. Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 12.3.5. Europe Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
- 12.3.6. Europe Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 12.3.7. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.3.9. Germany
  - 12.3.9.1. Overview
  - 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.9.3. Germany Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.3.9.4. Germany Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.3.9.5. Germany Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.3.9.6. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.3.10. UK
  - 12.3.10.1. Overview
  - 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.10.3. UK Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.3.10.4. UK Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.3.10.5. UK Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.3.10.6. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.3.10.7. UK Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.3.11. France
  - 12.3.11.1. Overview
  - 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.11.3. France Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.3.11.4. France Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.3.11.5. France Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.3.11.6. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.3.11.7. France Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.3.12. Italy
  - 12.3.12.1. Overview
  - 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.12.3. Italy Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.3.12.4. Italy Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.3.12.5. Italy Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.3.12.6. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.3.12.7. Italy Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.3.13. Spain
  - 12.3.13.1. Overview
  - 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.13.3. Spain Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.3.13.4. Spain Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.3.13.5. Spain Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.3.13.6. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.3.13.7. Spain Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.3.14. The Netherlands
  - 12.3.14.1. Overview
  - 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.14.3. The Netherlands Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.3.14.4. The Netherlands Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.3.14.5. The Netherlands Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.3.14.6. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.3.14.7. The Netherlands Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.3.15. Sweden
  - 12.3.15.1. Overview
  - 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.15.3. Sweden Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.3.15.4. Sweden Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.3.15.5. Sweden Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.3.15.6. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.3.15.7. Sweden Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.3.16. Russia
  - 12.3.16.1. Overview
  - 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.16.3. Russia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.3.16.4. Russia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.3.16.5. Russia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.3.16.6. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.3.16.7. Russia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.3.17. Poland
  - 12.3.17.1. Overview
  - 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.17.3. Poland Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.3.17.4. Poland Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.3.17.5. Poland Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.3.17.6. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.3.17.7. Poland Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.3.18. Denmark
  - 12.3.18.1. Overview
  - 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.18.3. Denmark Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.3.18.4. Denmark Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.3.18.5. Denmark Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.3.18.6. Denmark Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.3.18.7. Denmark Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.3.19. Rest of Europe
  - 12.3.19.1. Overview
  - 12.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.3.19.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.3.19.4. Rest of the Europe Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.3.19.5. Rest of the Europe Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.3.19.6. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.3.19.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.4. Asia Pacific (APAC)
- 12.4.1. Overview
- 12.4.2. Disease-Modifying Agents Key Manufacturers in Asia Pacific
- 12.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.4.4. APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 12.4.5. APAC Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
- 12.4.6. APAC Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 12.4.7. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.4.8. APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.4.9. China
  - 12.4.9.1. Overview
  - 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.9.3. China Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.4.9.4. China Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.4.9.5. China Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.4.9.6. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.4.9.7. China Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.4.10. India
  - 12.4.10.1. Overview
  - 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.10.3. India Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.4.10.4. India Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.4.10.5. India Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.4.10.6. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.4.10.7. India Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.4.11. Japan
  - 12.4.11.1. Overview
  - 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.11.3. Japan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.4.11.4. Japan Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.4.11.5. Japan Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.4.11.6. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.4.12. South Korea
  - 12.4.12.1. Overview
  - 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.12.3. South Korea Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.4.12.4. South Korea Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.4.12.5. South Korea Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.4.12.6. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.4.13. Australia
  - 12.4.13.1. Overview
  - 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.13.3. Australia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.4.13.4. Australia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.4.13.5. Australia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.4.13.6. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.4.14. Indonesia
  - 12.4.14.1. Overview
  - 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.4.14.4. Indonesia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.4.14.5. Indonesia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.4.14.6. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.4.14.7. Indonesia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.4.15. Thailand
  - 12.4.15.1. Overview
  - 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.15.3. Thailand Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.4.15.4. Thailand Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.4.15.5. Thailand Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.4.15.6. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.4.15.7. Thailand Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.4.16. Philippines
  - 12.4.16.1. Overview
  - 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.16.3. Philippines Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.4.16.4. Philippines Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.4.16.5. Philippines Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.4.16.6. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.4.17. Taiwan
  - 12.4.17.1. Overview
  - 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.17.3. Taiwan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.4.17.4. Taiwan Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.4.17.5. Taiwan Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.4.17.6. Taiwan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.4.17.7. Taiwan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.4.18. Vietnam
  - 12.4.18.1. Overview
  - 12.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.18.3. Vietnam Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.4.18.4. Vietnam Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.4.18.5. Vietnam Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.4.18.6. Vietnam Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.4.18.7. Vietnam Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.4.19. Rest of APAC
  - 12.4.19.1. Overview
  - 12.4.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.4.19.3. Rest of APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.4.19.4. Rest of APAC Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.4.19.5. Rest of APAC Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.4.19.6. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.4.19.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.5. Latin America (LATAM)
- 12.5.1. Overview
- 12.5.2. Disease-Modifying Agents Key Manufacturers in Latin America
- 12.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.5.4. LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 12.5.5. LATAM Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
- 12.5.6. LATAM Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 12.5.7. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.5.8. LATAM Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.5.9. Brazil
  - 12.5.9.1. Overview
  - 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.5.9.3. Brazil Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.5.9.4. Brazil Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.5.9.5. Brazil Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.5.9.6. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.5.10. Mexico
  - 12.5.10.1. Overview
  - 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.5.10.3. Mexico Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.5.10.4. Mexico Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.5.10.5. Mexico Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.5.10.6. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.5.11. Argentina
  - 12.5.11.1. Overview
  - 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.5.11.3. Argentina Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.5.11.4. Argentina Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.5.11.5. Argentina Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.5.11.6. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.5.12. Colombia
  - 12.5.12.1. Overview
  - 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.5.12.3. Colombia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.5.12.4. Colombia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.5.12.5. Colombia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.5.12.6. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.5.13. Rest of LATAM
  - 12.5.13.1. Overview
  - 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.5.13.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.5.13.4. Rest of LATAM Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.5.13.5. Rest of LATAM Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.5.13.6. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12.6. Middle East and Africa
- 12.6.1. Overview
- 12.6.2. Disease-Modifying Agents Key Manufacturers in Middle East and Africa
- 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
- 12.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
- 12.6.6. Middle East and Africa Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
- 12.6.7. Middle East and Africa Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
- 12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.6.9. Saudi Arabia
  - 12.6.9.1. Overview
  - 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.9.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.6.9.4. Saudi Arabia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.6.9.5. Saudi Arabia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.6.9.6. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.6.10. United Arab Emirates
  - 12.6.10.1. Overview
  - 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.10.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.6.10.4. United Arab Emirates Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.6.10.5. United Arab Emirates Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.6.10.6. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.6.11. Israel
  - 12.6.11.1. Overview
  - 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.11.3. Israel Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.6.11.4. Israel Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.6.11.5. Israel Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.6.11.6. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.6.12. Turkey
  - 12.6.12.1. Overview
  - 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.12.3. Turkey Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.6.12.4. Turkey Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.6.12.5. Turkey Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.6.12.6. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.6.13. Algeria
  - 12.6.13.1. Overview
  - 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.13.3. Algeria Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.6.13.4. Algeria Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.6.13.5. Algeria Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.6.13.6. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.6.14. Egypt
  - 12.6.14.1. Overview
  - 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.14.3. Egypt Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.6.14.4. Egypt Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.6.14.5. Egypt Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.6.14.6. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.6.15. Iran
  - 12.6.15.1. Overview
  - 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.15.3. Iran Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.6.15.4. Iran Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.6.15.5. Iran Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.6.15.6. Iran Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.6.15.7. Iran Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.6.16. Qatar
  - 12.6.16.1. Overview
  - 12.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.16.3. Qatar Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.6.16.4. Qatar Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.6.16.5. Qatar Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.6.16.6. Qatar Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.6.16.7. Qatar Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
- 12.6.17. Rest of MEA
  - 12.6.17.1. Overview
  - 12.6.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
  - 12.6.17.3. Rest of MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
  - 12.6.17.4. Rest of MEA Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
  - 12.6.17.5. Rest of MEA Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  - 12.6.17.6. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  - 12.6.17.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)

13. Key Vendor Analysis- Disease-Modifying Agents Industry

13.1. Competitive Benchmarking
- 13.1.1. Competitive Dashboard
- 13.1.2. Competitive Positioning
13.2. Company Profiles
- 13.2.1. Biogen Inc.
- 13.2.2. Merck KGaA
- 13.2.3. Sanofi
- 13.2.4. Pfizer Inc.
- 13.2.5. Teva Pharmaceutical Industries Ltd.
- 13.2.6. Novartis AG
- 13.2.7. F. Hoffmann-La Roche Ltd.
- 13.2.8. AbbVie Inc.
- 13.2.9. Johnson & Johnson
- 13.2.10. Amgen Inc.
- 13.2.11. Eli Lilly and Company
- 13.2.12. Bristol Myers Squibb
- 13.2.13. UCB S.A.
- 13.2.14. Bayer AG
- 13.2.15. Viatris Inc.
- 13.2.16. Fresenius Kabi
- 13.2.17. Accord Healthcare
- 13.2.18. Others

14. 360 Degree Analyst View

15. Appendix

15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격